94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1502701
This article is part of the Research Topic Immunological Aspects and Immunotherapy in Gynecologic Cancers View all articles
Analysis of the Efficacy and Safety of Camrelizumab Combined with Chemotherapy for Cervical Cancer Treatment
Provisionally accepted- 1 Chongqing Medical University, Chongqing, China
- 2 Department of Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Objectives:In this study, we explored the effectiveness and safety of the immune checkpoint inhibitor camrelizumab in combination with chemotherapy for the treatment of cervical cancer by investigating adverse effects and changes in tumor volume, tumor activity, and biochemical indices.Methods: In this retrospective analysis, the experimental group was administered intravenous camrelizumab in conjunction with a TP regimen (consisting of a paclitaxel analog and a platinum analog), while the control group was given only the TP regimen. The effectiveness of solid tumors, SCC-Ag values, tumor volume, and apparent diffusion coefficient (ADC) values, as well as adverse responses, were compared between the two groups.Results: In the experimental group, 11 cases (22.45%) exhibited complete remission (CR), 27 cases (55.10%) demonstrated partial resolution (PR), and 11 cases (22.45%) showed stable disease (SD). The objective remission rate (ORR) was 77.55%, and the disease control rate (DCR) was 100%. In the control group, 10 cases (25.64%) exhibited CR, 18 cases (46.15%) demonstrated PR, 9 cases (23.08%) exhibited SD, and 2 cases (5.13%) exhibited disease progression. The ORR was 71.79%, and the DCR was 94.87%. A significant difference was observed between the two groups regarding the post-treatment SCC-Ag value, pre-treatment minimum ADC (minADC), and the change in size of minADC before and after treatment (P < 0.05).A comparison of the pre-and post-treatment size changes in tumor volume in patients with stage IIA2 cancer revealed significant differences (p < 0.05). No adverse responses of grade 3 or higher were detected.Conclusions: Our analysis showed that the combination of camrelizumab and chemotherapy effectively reduced tumor size and malignancy in cervical cancer treatment, demonstrating robust anti-tumor activity with a favorable safety profile.
Keywords: cervical cancer, Immunotherapy, camrelizumab, PD-1, combined therapy
Received: 27 Sep 2024; Accepted: 06 Feb 2025.
Copyright: © 2025 Yang, Yang, Wang, Mu and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiao-Ling Mu, Department of Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Bo Yan, Chongqing Medical University, Chongqing, 400016, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.